We use the latest evidence based methods to help you achieve long-term success through a combination of interventions as follows:
COMPREHENSIVE EVALUATION for causes of weight gain.
BEHAVIOR: Learn behavioral intervention tools to develop healthy lifestyle habits and enhance your weight loss efforts.
EATING: Examine how different types of foods and nutrients can assist in weight loss while also promoting good health.
ACTIVITY: Discuss about the role of different types of exercise to help with weight loss and weight maintenance.
MEDICATIONS: We prescribe all FDA-approved medications for weight loss and cardiovascular risk reduction.
FDA-Approved Medications For Weight Loss
(GLP-1 Receptor Agonist)
Wegovy, Ozempic, Rybelsus
(Adrenergic Stimulant, FDA approved for short term use)
Adipex, Lomaira, Ionamin
(Stimulant/Neurostabilizer of GABA Pathway)
(Opioid Receptor Antagonist/ Dopamine Pathway)
(Pancreatic Lipase inhibitor)
(GIP/GLP-1 Receptor Agonist)
Weight loss varies widely among patients when using any of the above medications. In other words, not everybody loses the same amount of weight with one type of medication. Sometimes one medication must be complemented with another medication.
THE ABOVE MEDICATIONS are FDA-approved for BMI >30 (kg/m2) or for BMI >27 (kg/m2) plus co-morbidity, and are to be used only in conjunction with lifestyle modifications.
THE ABOVE LIST DOES NOT INCLUDE:
Metformin - has not been approved as a weight-loss drug. A 2020 meta-analysis of metformin studies in adults with obesity showed modest (<5%) weight reduction with metformin when used as an adjunct to lifestyle; however, it is used "off label" for weight loss and some people may respond more than others.
SGLT2 inhibitors (e.g. Dapagliflozin (Farxiga) or Empagliflozin (Jardiance) and other similar medications from the same class can aid weight loss but not significantly.
Setmelanotide (e.g. Imcivree) is used only based on genetic testing for those with genetic abnormalities causing obesity, usually diagnosed in childhood.
Liraglutide (Saxenda) belongs to the GLP-1 agonist class and is also approved for treatment of obesity.